Sun Pharma's SPARC reduces workforce by 40%, consolidating operations and shifting to a hybrid research model for efficiency.

Sun Pharmaceutical Industries Ltd. closed 4.84% short of its 52-week high of 1,850.95 rupees, which the company achieved on May 2nd.

They have also shared an outlook on pharma, telecom, internet platforms, banking, metals and consumer sectors, alongside ...

Halvio Capital returned 5.62 percent this quarter while exploring international value opportunities. View our latest partner ...

India’s pharmaceutical sector is heading into a split-screen 2026, with brokerage commentary pointing to a year marked by ...

Gujarat is launching a major push into AI and the digital economy with a dedicated IT-AI cluster near GIFT City and the ...

The 2025 contraction marks the steepest decline in both the number of billionaire promoters and their aggregate wealth since ...

If the weather forecast is to be believed, something miraculous is about to happen in San Francisco. For the first time in ...

PN visited BRC-accredited Expac in Preston to see how the formulations and full-service co-packing specialist is building on ...

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

ANOTHER day, another police ­scandal. The Met Police has revealed it hired thousands of officers and staff in the past few ...

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...